Comparison of effects of BD Micro Fine Plus and NANOPASS Needle II in diabetic patients with insulin therapy

Comparison of effects of BD Micro Fine Plus and NANOPASS Needle II in diabetic patients with insulin therapy - Comparison of effects of 32G 4mm and 34G 4mm insulin pen needle in diabetic patients with insulin therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023673

Enrollment

Registered

2016-08-19

Start date

2016-08-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

After obtaining informed consent from all patients, they switched from 32G 4mm needles to 34G 4mm needles.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic patients who perform self-injection of insulin with pen injectors.

Exclusion criteria

Exclusion criteria: Patients who have trouble determining the pain intensity, or any other criterion associated with the questionnaire.

Design outcomes

Primary

Measure	Time frame
Assessment of puncture site pain using the visual analogue scale	—

Secondary

Measure	Time frame
HbA1c, Adverse events (dribbling, bleeding, needle breakage)	—

Countries

Japan

Contacts

Public ContactDaisuke Saito

Kansai Rosai Hospital Diabetes and Endocrinology

dsaitou@juntendo.ac.jp06-6416-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026